Target type: biologicalprocess
Any process that increases the rate, frequency, or extent of the process of immune complex clearance by monocytes or macrophages. [GOC:BHF]
**Positive Regulation of Immune Complex Clearance by Monocytes and Macrophages**
Immune complexes (ICs), formed when antibodies bind to antigens, are a crucial part of the adaptive immune response. However, their accumulation can lead to detrimental effects, including autoimmune diseases. Therefore, efficient clearance of ICs is essential for maintaining immune homeostasis. Monocytes and macrophages, phagocytic cells of the innate immune system, play a pivotal role in this process.
**Steps Involved:**
1. **IC Recognition:**
* Monocytes and macrophages express a variety of receptors capable of recognizing ICs, including Fc receptors (FcRs) and complement receptors (CRs).
* FcRs bind to the Fc portion of antibodies, while CRs bind to complement proteins that become deposited on the surface of ICs.
* These receptors can work in synergy, enhancing IC recognition and uptake.
2. **IC Internalization:**
* Once recognized, ICs are internalized by phagocytosis, a process where the cell engulfs the ICs into a membrane-bound vesicle called a phagosome.
* This process is driven by cytoskeletal rearrangements and involves the formation of pseudopodia, extensions of the cell membrane, that surround and enclose the IC.
3. **Phagosome Maturation and IC Degradation:**
* After internalization, the phagosome undergoes maturation, fusing with lysosomes, which are cellular organelles containing digestive enzymes.
* Lysosomal enzymes, such as proteases and nucleases, degrade the IC components, including antibodies and antigens, into smaller fragments.
4. **Antigen Presentation:**
* In addition to degrading ICs, macrophages can also process antigens derived from ICs and present them to T cells, thereby contributing to the adaptive immune response.
**Regulation of IC Clearance:**
* **Cytokines and Chemokines:**
* Cytokines, such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), can enhance IC clearance by monocytes and macrophages.
* Chemokines, such as CCL2 and CCL5, recruit these cells to sites of inflammation where ICs accumulate.
* **Complement System:**
* The complement system, a cascade of proteins that activate upon recognition of pathogens or ICs, can enhance IC clearance by promoting opsonization (coating of ICs with complement proteins) and facilitating their uptake by phagocytes.
* **Receptor Expression and Signaling:**
* The expression and signaling of FcRs and CRs are tightly regulated, ensuring that ICs are efficiently cleared without triggering excessive inflammation.
**Consequences of Impaired IC Clearance:**
* **Autoimmune Diseases:** Accumulation of ICs in tissues can lead to immune complex-mediated diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
* **Inflammation:** IC deposition can trigger inflammation, potentially contributing to tissue damage.
**Conclusion:**
Positive regulation of IC clearance by monocytes and macrophages is essential for maintaining immune homeostasis and preventing autoimmune diseases. This process involves a complex interplay of receptors, signaling pathways, and cellular machinery, ensuring efficient and controlled removal of ICs from circulation.'
"
Protein | Definition | Taxonomy |
---|---|---|
C-C chemokine receptor type 2 | A C-C chemokine receptor type 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P41597] | Homo sapiens (human) |
Phospholipase A2 group V | A phospholipase A2 group V that is encoded in the genome of human. [PRO:DNx, UniProtKB:P39877] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
amiodarone | amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias. Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance. | 1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound | cardiovascular drug |
disulfiram | organic disulfide; organosulfur acaricide | angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor | |
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
nifedipine | Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | C-nitro compound; dihydropyridine; methyl ester | calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent |
dibenzothiazyl disulfide | dibenzothiazol-2-yl disulfide : An organic disulfide resulting from the formal oxidative coupling of the thiol groups of two molecules of 1,3-benzothiazole-2-thiol. It is used as an accelerator in the rubber industry. dibenzothiazyl disulfide: vulcanizing accelerant | benzothiazoles; organic disulfide | allergen |
1-naphthylisothiocyanate | 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage. | isothiocyanate | insecticide |
plerixafor | plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2 | azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound | anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant |
rosiglitazone | aminopyridine; thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug | |
3-octylthio-1,1,1-trifluoro-2-propanone | 3-octylthio-1,1,1-trifluoro-2-propanone: a pesticide synergist; inhibits juvenile hormone esterase | ||
varespladib | aromatic ether; benzenes; dicarboxylic acid monoamide; indoles; monocarboxylic acid; primary carboxamide | anti-inflammatory drug; antidote; EC 3.1.1.4 (phospholipase A2) inhibitor | |
fasudil hydrochloride | fasudil hydrochloride : A hydrochloride obtained by reaction of fasudil with one equivalent of hydrochloric acid. | hydrochloride | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; neuroprotective agent; nootropic agent; vasodilator agent |
tak 779 | |||
bay 11-7085 | BAY11-7085 : A sulfone that is benzene substituted by [(E)-2-cyanoethenyl]sulfonyl and tert-butyl groups at position 1 and 4, respectively. It is an irreversible inhibitor of IkappaB-alpha phosphorylation in cells (IC50 = 10 muM) and prevents the activation of NF-kappaB. | benzenes; nitrile; sulfone | anti-inflammatory agent; antibacterial agent; antineoplastic agent; apoptosis inducer; autophagy inducer; EC 2.7.11.10 (IkappaB kinase) inhibitor; ferroptosis inducer; NF-kappaB inhibitor |
ucb 35625 | UCB 35625: J-113863 is the (trans)-isomer; structure in first source | ||
ym 26734 | YM 26734: inhibits group II phospholipase A2; structure given in first source | ||
indoxam | indoxam: structure in first source | ||
rs 504393 | RS 504393: structure in first source | 1,3-oxazoles | |
incb3344 | INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist | ||
amd 070 | mavorixafor: a derivative of AMD3100; a CXCR4 blocker | aminoquinoline | |
cenicriviroc | cenicriviroc : A member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). cenicriviroc: an inhibitor of HIV-1 | aromatic ether; benzazocine; diether; imidazoles; secondary carboxamide; sulfoxide | anti-HIV agent; anti-inflammatory agent; antirheumatic drug; chemokine receptor 2 antagonist; chemokine receptor 5 antagonist |
incb 3284 | INCB 3284: a CCR2 receptor antagonist | ||
azd8309 | AZD8309: CXCR2 inhibitor | ||
n-(carbamoylmethyl)-3-trifluoromethyl benzamido-4-chlorobenzyl 3-aminopyrrolidine |